Lactobacillus rhamnosus GG ATCC 53103 ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
97Ulcerative colitis1

97. Ulcerative colitis


Clinical trials : 2,527 Drugs : 1,465 - (DrugBank : 259) / Drug target genes : 144 - Drug target pathways : 202
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04102852
(ClinicalTrials.gov)
September 30, 201917/9/2019Lactobacillus Rhamnosus GG (ATCC 53103) in Mild-moderately Active UC PatientsThe Role of Lactobacillus Rhamnosus GG (ATCC 53103) in the Modulation of the Inflammatory Process in the Mucosa of Ulcerative Colitis (UC) Patients With Mild-moderate Clinical ActivityUlcerative Colitis Chronic Mild;Ulcerative Colitis Chronic ModerateDietary Supplement: Lactobacillus rhamnosus GG ATCC 53103San Giovanni Addolorata HospitalOnlus S. AndreaRecruiting18 Years65 YearsAll80Phase 1/Phase 2Italy